drugset
drugset / Trial / NCT03456349

Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care

NCT03456349 ↗

Phase 1 Completed 60 enrolled Nxera Pharma UK Limited Allergan · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Multi-centre study of HTL0018318 in patients with Alzheimer's disease as an add-on to standard-of-care

Timeline

Start
2017-11-10
Primary completion
2018-07-16
Completion
2018-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject HTL0018318 Unknown — —

Indications

Alzheimer disease